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AbstrAct:
Galectins are a family of β-galactoside-binding lectins that exert diverse 
extracellular and intracellular effects. Galectin-7 and galectin-1 show opposing 
effects on proliferation and survival in different cell types. Galectin-7 is a p53-induced 
gene and an enhancer of apoptosis, whereas galectin-1 induces tumorigenicity 
and resistance to apoptosis in several types of cancers. We show here that in cells 
derived from neurofibromin-deficient (Nf1–/–) malignant peripheral nerve sheath 
tumors (MPNSTs), Ras inhibition by S-trans,trans-farnesylthiosalicylic-acid (FTS; 
Salirasib) shifts the pattern of galectin expression. Whereas FTS decreased levels of 
both active Ras and galectin-1 expression, it dramatically increased both the mRNA 
and protein expression levels of galectin-7. Galectin-7 accumulation was mediated 
through JNK inhibition presumably resulting from the observed induction of p53, 
and was negatively regulated by the AP-1 inhibitor JDP2. Expression of galectin-7 
by itself decreased Ras activation in ST88-14 cells and rendered them sensitive 
to apoptosis. This observed shift in galectin expression pattern together with the 
accompanying shift from cell proliferation to apoptosis represents a novel pattern of 
Ras inhibition by FTS. This seems likely to be an important phenomenon in view of the 
fact that both enhanced cell proliferation and defects of apoptosis constitute major 
hallmarks of human cancers and play a central role in the resistance of MPNSTs to 
anti-cancer treatments. These findings suggest that FTS, alone or in combination with 
chemotherapy agents, may be worth developing as a possible treatment for MPNSTs.
INtrODUctION
The Ras superfamily control many cellular functions 
including cell growth, differentiation, motility and 
survival [1-6] and play a major role in cell transformation. 
They alternate between a GDP-bound (inactive) and a 
GTP-bound (active) state through the action of guanine 
nucleotide exchange factors (RasGEFs) and GTPase 
activating proteins (RasGAPS). Active Ras was found to 
interact specifically with two members of the galectins 
family; galectin-1 and galectin-3. [7-9].
Galectins are a phylogenetically conserved family 
of lectins that share consensus amino-acid sequences 
and the carbohydrate recognition domain responsible for 
β-galactoside binding [10]. They are located within the 
cells (cytoplasm and nucleus) and are also secreted into 
the extracellular space. Although originally considered 
only as extracellular structural elements, a large body of 
evidence testifying to their role in intracellular signaling 
has accumulated over the last decade. Galectins have 
been implicated in several cellular processes, including 
apoptosis, cell survival, cell adhesion, immune response, 
and gene expression (reviewed in [11] and [12]).  
Overexpression of galectin-1, a prototype member of 
this family, has been documented in many different tumor 
types [13-15], and in various aspects of tumor biology 
including migration and invasiveness, chemoresistance 
[16], angiogenesis [17], immune escape [18] and 
malignant progression [19-21]. Galectin-1 interacts with 
the small GTPases H-Ras-GTP in the plasma membrane, 
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resulting in stabilization of H-Ras-GTP, clustering of 
H-Ras-GTP and galectin-1 in non-raft microdomains [22], 
subsequent binding to Raf-1 (but not to PI3K or Ral-GEF 
[7, 23]), activation of the ERK signaling pathway, and 
increased cell transformation [7]. 
As opposed to galectin-1, galectin-7—another 
member of the galectin superfamily—displays pro-
apoptotic activity in various types of cells. Expression of 
galectin-7 is induced in the early steps of p53-mediated 
apoptosis and has been designated as the product of the 
p53-induced gene 1 (PIG1) [24]. A major function of 
p53 is control of apoptosis homeostasis [25], and it is the 
most frequently mutated gene in human tumors [25]. As 
opposed to galectin-7, galectin-1 is downregulated by 
p53 in glioma cells [26]. In line with its pro-apoptotic 
activity, galectin-7 inhibits DLD-1 cell proliferation 
in vitro and in vivo [27, 28] and is downregulated in 
transformed keratinocytes [29]. UVB irradiation induces 
apoptosis and galectin-7 expression in dependence 
with p53 [30, 31]. Ectopic expression of galectin-7 in 
HeLa and DLD-1 cells renders them more sensitive to a 
variety of apoptotic triggers, causes enhanced caspase-3 
activity and poly(ADP-ribose) polymerase cleavage, and 
accelerated mitochondrial cytochrome-C release [32]. In 
addition, galectin-7 was found to bind directly to Bcl-2 
in the mitochondria and to sensitize the mitochondria to 
apoptotic signals [33]. 
While galectin-7 negatively regulates some tumor 
types, it can stimulate the growth and/or development 
of others [34-37]. It thus seems that galectin-7 can act 
either as a positive or as a negative regulatory factor in 
tumor development, depending on the histological type 
of the tumor. Although the effect of p53 on galectin-7 
expression is well established, little is known about how 
its transcription is regulated. 
Although, as mentioned above, changes in 
expression levels of galectins have been implicated 
in many types of diseases including cancer, the role 
of galectins in neurofibromatosis type 1 (NF1) is still 
unknown. NF1 has an autosomal dominant mode of 
inheritance with a prevalence of about 1 in 3000 live 
births. It harbors a variety of phenotypes. The hallmark 
of NF1 is the neurofibroma, a benign peripheral nerve 
tumor comprised of transformed Schwann cells [38]. 
Neurofibromas undergo transformation into aggressive and 
chemotherapy-resistant malignant peripheral nerve sheath 
tumors (MPNSTs), which are prone to life-threatening 
metastasis [39]. 
Loss of neurofibromin Ras-GAP activity is 
associated with increased Ras-GTP and overactivation 
of Ras effectors [40], and reviewed in [41], leading to 
NF1 [42, 43]. The role of Ras in NF1-based malignancy 
suggests that Ras inhibitors such as S-trans, trans-
farnesylthiosalicylic acid (FTS; Salirasib), which 
interfere with Ras-membrane anchorage [3], are likely 
to have useful therapeutic activity. Importantly, FTS 
interferes, both in vitro and in vivo, with the transformed 
phenotype of NF1-associated MPNST cell lines [44]. 
We  recently discovered that FTS reverses the epithelial-
mesenchymal (EMT)-like transition  phenotype of NF1-
deficient MPNST cells by perturbing the signaling of bone 
morphogenetic protein (BMP)4 and transforming growth 
factor (TGF)-β1 to SMAD-dependent and ERK-dependent 
pathways, inhibiting motility, spreading and gelatinase 
secretion, and alternating gene expression [45]. 
The activator protein-1(AP)-1 transcription-factor 
complex, which participates actively in cell proliferation, 
differentiation and cell transformation, is composed of 
homodimeric and heterodimeric complexes consisting of 
members of the Jun: Fos and Jun dimerization protein 2 
(JDP2), activating transcription factors (ATFs) and other 
proteins [46]. c-jun, which is phosphorylated by c-Jun 
terminal kinase (JNK) through Ras-induced signaling 
[47-49], cooperates with Ras in cell transformation [50, 
51] and has been shown to interfere with p53-induced 
apoptosis [52, 53]. JDP2 heterodimerizes with c-jun [54], 
and functions as a repressor of the AP-1 protein family 
by interfering with the c-jun-induced transformation 
[55]. JDP2 inhibits cell proliferation [56] and cell 
transformation, both induced by Ras [57]. Thus, on the 
one hand JDP2 inhibits cell transformation induced by 
Ras; on the other hand, it has been identified as a candidate 
oncogene in mouse hepatocellular carcinoma [58] and in a 
high-throughput screen in mice [59-61]. 
Here we show that Ras inhibition in NF1-deficient 
MPNST cells dramatically increases galectin-7 expression 
and decreases the expression of galectin-1. The increase 
in galectin-7 was dependent on JNK inhibition. We found 
that expression of galectin-7 itself modulates Ras signaling 
and renders MPNST cells more sensitive to apoptosis, 
suggesting the possible existence of cross-talk between 
Ras and galectin-7.
rEsULts
ras inhibition induces galectin-7 and reduces 
galectin-1 expression in NF1-deficient MPNST 
cells
Ras inhibition by FTS in NF1-deficient MPNST 
cells inhibits their transformed phenotype both in vitro 
and in vivo [44], reverses their EMT-like phenotype, and 
alters gene expression [45]. One of the most significantly 
upregulated genes in our microarray analysis was the 
β-galactosidase-binding lectin, galectin-7, with an increase 
of 22.6-fold in its transcript in ST88-14 cells after FTS 
treatment. Galectin-7 is considered to be an apoptotic 
regulator, whose mRNA is highly induced by p53 [24] 
and whose expression sensitizes HeLa and DLD-1 cells to 
apoptosis through enhanced caspase-3 activity [32]. 
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Figure 1: Fts induces a shift in galectin-1 and galectin-7 expression levels. (A) ST88-14 cells were treated for 48 h with 
FTS (75 µM, 5% FCS) or vehicle followed by immunoblotting with galectin-7 or galectin-1 antibodies. ERK2 served as loading control. 
Immunoblots from a typical experiment are shown in the left panel. Graphs depict quantification of galectin-1 (right) and galectin-7 (center) 
(**p<0.01, ***p<0.001, n=6). (B) Relative expression of galectin-7 and galectin-1 mRNA were detected by real-time PCR (*p<0.005, n=4 
and n=3 respectively). (C) ST88-14 cells were treated with FTS (75 µM, 5% FCS) for the indicated times and immunoblotted with anti-
galectin-7, anti pERK 1/2 or anti ERK2 antibodies or subjected to real-time PCR for assay of galectin-7 mRNA. A typical experiment is 
shown. (D) ST88-14 cells were transfected with GFP or GFP-H-Ras(17N) (dnRas) by nucleofection, as described in Methods. After 24 h 
cells were lysed and subjected to western blot analysis with the indicated antibodies. Typical blots are shown in the left panel; right panel 
depicts quantification of galectin-7 (n=3, *p<0.05). ERK2 served as loading control.
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Treatment with FTS (75 µM, 48 h, 5% serum) 
markedly increased the amounts of galectin-7 protein in 
the NF1-deficient MPNST cell lines ST88-14 (Figure 
1A, 211% of control, p<0.001, n=6) and T265p21 
(supplementary Figure 1A). No such increase was seen 
after FTS treatment of the non-NF1 STS26T cell line or 
of the NF1-deficient cell line 90-8 (Supplementary Figure 
1A). It is worth noting that both of the cell lines in which 
Ras inhibition induced an increase in galectin-7 (i.e., 
ST88-14 and T265P21) harbor wild-type p53, whereas 
the two cell lines in which galectin-7 was unaffected by 
FTS harbor mutated p53 [66]. FTS treatment of ST88-
14 cells also increased their galectin-7 mRNA content, 
as detected by real-time PCR (Figure 1B, 1040% of 
control, p<0.05, n=4). In contrast to galectin-7 mRNA, our 
microarray analysis indicated that galectin-1 mRNA was 
downregulated by 14 fold following FTS treatment, a trend 
that was validated by real-time PCR analysis (Figure 1B, 
76% of control, p<0.05, n=4) and was accompanied by a 
decrease in galectin-1 protein in ST88-14 cells (Figure 1A, 
64% of control, p<0.01, n=4). These results are consistent 
with earlier reports of galectin-1 downregulation by 
inhibition of Ras [7, 8].
To follow the dynamics of the FTS-induced increase 
in galectin-7 mRNA and protein, we treated ST88-14 cells 
with FTS (75 µM, 5% FCS), and monitored the change 
over time by real-time PCR and Western blotting for 
different time periods From 12 h after FTS treatment 
galectin-7 mRNA increased in a time-dependent manner, 
reaching a plateau at 48 h after treatment. Galectin-7 
protein levels started to increase at 24 h after treatment 
and reached a maximum at 72 h (Figure 1C).
Figure 2: JNK inhibition increases galectin-7 protein and mrNA levels. (A) ST88-14 cells were treated for 48 h with U0126 (10 
µM), LY294002 (20 µM), SB203580 (4 µM), SP600125 (25 mM), FTS (75 µM) or vehicle, followed by immunoblotting with the indicated 
antibodies. (B) Quantification of ST88-14 treated as in (A) and assayed for galectin-7 protein by western blotting (upper panel) or for 
mRNA by real-time PCR (lower panel). SP for SP600125 (C) ST88-14 cells were transfected with GFP or GFP-TMA67 by nucleofection, 
as described in Methods. After 24 h, cells were lysed and subjected to western blot analysis with the indicated antibodies. Typical blots 
are shown in the left panel; right panel depicts quantification of galectin-7 protein expression (n=3, *p<0.05). GAPDH served as loading 
control.
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To determine whether the FTS-induced upregulation 
in galectin-7 protein was a result of the Ras inhibition, 
we evaluated galectin-7 in ST88-14 and T265P21 cells 
transfected with GFP-H-Ras(17N) (dnRas)  or, as a 
control, with GFP. Transfection of dnRas induced a 
significant increase in galectin-7 expression levels in both 
the ST88-14 (Figure 1D, 280% of GFP, p<0.05, n=4) 
and the T265p21 cells (Supplementary Figure 1B, 122% 
of GFP, p<0.06, n=3). As expected, the cells transfected 
with dnRas exhibited decreased ERK phosphorylation, 
indicating that the transfected vector was indeed reducing 
Ras activation (Figure 1D). This strengthens the notion 
that the FTS-induced increase in galectin-7 is a result of 
Ras inhibition. 
The protein synthesis inhibitor cycloheximide 
completely inhibited the FTS-induced increase in 
galectin-7 (Supplementary Figure 1C), further supporting 
the notion that regulation of the transcription was mediated 
by Ras.
Galectin-7 expression is induced by JNK 
inhibition
To find out which Ras-signaling pathway leads 
to the galectin-7 upregulation described above, we 
employed several chemical inhibitors of some of the most 
prominent Ras effectors: U0126, a MEK inhibitor; LY 
294002, a PI3K inhibitor; SB203580, a p38 inhibitor, and 
SP600125, a JNK inhibitor. Western blot analysis showed 
that phosphorylation of all the relevant target proteins was 
curbed by their respective inhibitors (Figure 2A), with 
the exception of p38, on which SB203580 had no effect. 
Notably, in ST88-14 cells inhibition of the JNK pathway 
alone induced a pronounced increase in galectin-7 protein 
(Figure 2A, B), which was accompanied by an increase 
in galectin-7 mRNA (Figure 2B). Treatment of T265p21 
cells with SP600125 also resulted in a robust increase 
in galectin-7, like that in ST88-14 cells (Supplementary 
Figure 2A). 
By using a dominant-negative c-jun protein 
(TAM67), we further verified that inhibition of JNK and 
its phosphorylation target c-jun indeed induced galectin-7 
protein. Transient transfection with TAM67 significantly 
increased galectin-7 expression in ST88-14 cells, 
strengthening the notion that c-jun is a major player in the 
Ras-induced increase in galectin-7. 
ras inhibition induces galectin-7 transcription 
through p53, c-jun, and JDP2
Following the notion that galectin-7 accumulates 
in response to inhibition of Ras or c-jun, we examined 
whether Ras inhibition in ST88-14 cells directly inhibits 
c-jun. A decrease in phospho-c-jun in these cells was 
indeed observed after treatment with FTS (Figure 3A, 
67% of control, *p<0.05, n=3), suggesting that Ras 
inhibition induces galectin-7 expression by inhibiting 
c-jun activation. 
Expression of galectin-7 is regulated by the tumor 
suppressor p53 [24], which is one of the most frequently 
mutated genes in cancer [25]. Analysis of the promoter 
region of galectin-7 gene using a Genomatix Genome 
Analyzer (Genomatix Software GmbH [65]) indeed 
revealed a putative p53-binding site (Supplementary 
Figure 2B). ST88-14 cells harbor wild-type p53, although 
its levels under normal growth conditions are small. We 
therefore followed changes in the amounts of p53 protein 
after FTS-induced inhibition of Ras in ST88-14 and 
T265P21 cells. In agreement with results obtained in the 
case of colon cancer [67], treatment with FTS resulted 
in a significant accumulation of p53 protein (ST88: 
Figure 3B, 163% of control, ***p<0.001, n=5; T265P21: 
Supplementary Figure 2C, 213% of control, **p<0.01, 
n=3). 
Upregulation of p53 in ST88-14 cells was also found 
Figure 3: ras inhibition induces galectin-7 
transcription through p53 and c-jun. (A, B) ST88-
14 cells were treated for 48 h with FTS (75 µM, 5% FCS) or 
vehicle followed by immunoblotting with anti- p-c-jun and total 
c-jun (A) or anti-p53 (B) antibodies. GAPDH served as loading 
control. Immunoblots from a typical experiments are shown 
in the left panels; graphs depicting quantification{?depicting 
assay} of p-c-jun (A) or p53 (B) are shown in the right panel (A; 
*p<0.05, n = 3, B; ***p<0.001, n = 5). 
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here to lead to a significant decrease in the anti-apoptotic 
protein survivin (Fig 3C, 45% of control, p<0.01, n=5) and 
in its mRNA (Figure 3C, 8% of control, p<0.001, n=4). 
This was an interesting finding, in view of a report that 
transcription of survivin is repressed by wild-type p53 
[68, 69]. Our finding is also in line with the previously 
described decrease in survivin by FTS in U87 [70] and 
DLD1 cells [71]. 
Given our observations that JNK inhibition induced 
a dramatic increase in galectin-7 and that FTS itself 
inhibits c-jun phosphorylation, we searched for c-jun 
regulatory elements in the galectin-7 promoter. Using 
Genomatix, we found putative binding sites for AP-1 and 
for the AP-1 inhibitor JDP2 (Supplementary Figure 2B). 
Because JDP2 participates in the p53 signaling pathway 
[72] and is regulated by c-jun [73], we investigated its 
possible involvement in the regulation of galectin-7 
transcription. First, we analyzed changes in the amounts 
of JDP2 mRNA after FTS treatment. Figure 4A shows that 
JDP2 transcripts were increased by 2.5-fold in FTS-treated 
cells compared to control (**p<0.01, n=6). Inhibition of 
JNK by SP600125 also increased JDP2 mRNA (Figure 
4B, 1.7-fold compared to control, ** p<0.01, n=3). 
Other studies demonstrated the phosphorylation of JDP2 
on Thr148 by JNK leading the protein to proteasomal 
degradation [73], supporting the negative role of JNK on 
JDP2 levels.
Next, we examined effect of using a specific small 
interfering RNA (siRNA) to decrease JDP2 expression. 
Figure 4C shows that transfection of cells with a specific 
siRNA against JDP2 reduced JDP expression to 0.36-
fold of that obtained with a nonspecific siRNA (*p<0.05, 
n=3). In the latter transfected cells, the FTS-induced 
increase in JDP2 was maintained (Figure 4C, 2.8-fold of 
control; ***p<0.001, n=3), exactly as shown in Figure 
1A. However, JDP2-siRNA markedly decreased the 
FTS-induced JDP2 accumulation to 0.14-fold of that in 
the non-target-siRNA transfected cells treated with FTS. 
Surprisingly, after the former transfection, induction 
of galectin-7 mRNA in the FTS-treated cells showed a 
dramatic 83.3-fold increase compared to an increase of 
only 5.2-fold in the control FTS-treated cells transfected 
with non-target siRNA (Figure 4D). Accumulation of 
galectin-7 mRNA was also significantly increased without 
FTS treatment: in cells transfected with siRNA for JDP2 
and treated with vehicle, galectin-7 mRNA was 1.46-fold 
higher than in the nonspecific siRNA transfectants (Figure 
4D, **p<0.01, n=3).
Galectin-7 expression inhibits ras and sensitizes 
st88-14 cells to apoptosis
We have previously shown that galectin-1 
expression stabilizes Ras in its GTP-binding state and 
Figure 4: JDP2 inhibition boosts galectin-7 transcription. (A, B) ST88-14 cells were treated for 48 h in 5% FCS with FTS (A; 
75 µM) or with SP600125 (B; 25 mM). JDP2 mRNA was assayed by real-time PCR (**p<0.01; (A), n=6; (B), n=3). (C, D) ST88-14 cells 
transfected with non-targeting siRNA (si control) or with siRNA against JDP2 (si JDP2) were treated, 24 h after transfection, with FTS 
(75 µM, 5% FCS) or vehicle. JDP2 (C) and galectin-7 (D) mRNA were assayed by real-time PCR (*p<0.05, **p<0.01, ***p<0.001, n=3).
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that antisense galectin-1 reduces Ras activation [7]. 
Having detected an increase in galectin-7 and a decrease 
in galectin-1 in ST88-14 cells after Ras inhibition, we 
wanted to find out whether expression of galectin-7 
affects Ras activation. To that end, ST88-14 cells were 
infected with viruses containing galectin-7 DNA (ST88/
gal7) or, as a control, GFP (ST88/GFP). After selection 
and validation of expression, the amounts of Ras-GTP 
in the ST88/gal7 cells were compared to those in ST88/
GFP and in noninfected ST88-14 cells. Notably, stable 
expression of galectin-7 in ST88-14 cells resulted in a 
marked reduction of Ras activity to 58% of that in GFP-
infected or noninfected cells (Figure 5A, **p<0.01, n=3). 
We could not detect any significant changes in pERK, 
p-Akt or p-c-jun levels (data not shown). 
That galectin-7 expression sensitizes cells to 
caspase-mediated apoptosis induced by several agents 
has by now been well established [32]. Unpublished data 
from our lab has demonstrated that treatment of ST88-
14 cells with FTS together with several chemotherapy 
agents. i.e., paclitaxel, doxorubicin, or cisplatin induces 
a synergistic effect on cell proliferation and enhances cell 
death. We therefore examined whether the FTS-induced 
accumulation of galectin-7 might render NF1-deficient 
cells more sensitive to apoptosis. ST88-14 and ST88/
gal 7 cells were treated with different cell-death inducers 
(paclitaxel, cisplatin, or serum deprivation (0.2% FCS)) 
and assayed for cell viability using annexin-V/PI staining 
followed by FACS analysis. As shown in Figure 5B, 
expression of galectin-7 reduced the percentage of live 
(nonapoptotic) cells as indicated by negative staining 
for both PI and annexin-V. Those results indicate that 
galectin-7 expression sensitizes ST88-14 cells to apoptotic 
triggers, in agreement with the report by Kuwabara et al. 
[32].
Next, we examined the nature of galectin-7-induced 
susceptibility to apoptosis. Galectin-7 expression has 
been shown to cause enhanced caspase-3 activity [14, 
32] and to sensitize urothelial cancers to cisplatin [28]. In 
agreement with these findings we detected high levels of 
cleaved caspase-3 in ST88/gal7 cells, whereas in control 
Figure 5: Galectin-7 expression inhibits ras and 
sensitizes st88-14 cells to apoptosis. (A) Wild-type 
ST88-14 cells (ST88) or ST88-14 cells stably infected with 
GFP (ST88/GFP) or galectin-7 (ST88/gal7) were subjected to 
Ras-GTP pull-down assay and immunoblotted with anti-Ras, 
anti-galectin-7, or anti-GAPDH antibodies. Left panel depicts a 
typical experiment; quantification (% of control) is shown in the 
right panel (** p<0.01, n=3). (B) ST88 or ST88/gal7 cells were 
treated with paclitaxel (10 nM), cisplatin (1 μM), or vehicle in 
growth medium or under serum deprivation (0.2% FCS) for 24 
h, then collected, stained with FITC-conjugated annexin V and 
PI, and analyzed by flow cytometry (*p<0.05, **p<0.01, n=3). 
(C) ST88, ST88/GFP or ST88/gal7 cells (5% FCS, 48 h) were 
lysed and immunoblotted using cleaved caspase 3, galectin-7 
or GAPDH antibodies. Typical immunoblots are shown in the 
left panel and quantification of cleaved caspase 3 (% of control; 
**p<0.01, n=4) in the right panel.
Figure 6: Model depicting the galectin-1/galectin-7 
switch. High Ras-GTP increases galectin-1 expression 
and inhibits galectin-7 expression through JNK. Galectin-1 
itself stabilizes and increases Ras-GTP, thereby inducing 
transformation. Inhibition of Ras by FTS or dnRas reduces 
galectin-1 expression and induces robust expression of 
galectin-7. High levels of galectin-7 inhibit Ras activation and 
sensitize cells to apoptosis.
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cell lines the cleaved form of caspase-3 was undetectable 
(Figure 5C, **p<0.01, n=4).
DIscUssION
We show here that in the NF1-deficient ST88-
14 and T265P21 MPNST cell lines, Ras inhibition by 
FTS or dnRas dramatically induced expression of the 
pro-apoptotic protein galectin-7 (Figure 1 for ST88-14, 
Supplementary Figure 1B for T265P21). This was evident 
(for ST88-14) from the microarray analysis (22.6-fold 
increase), RT‒PCR (1040% of control), and western 
blotting (211% of control). In contrast, FTS treatment 
reduced the expression of galectin-1, as also shown by 
microarray analysis, real-time PCR, and western blot 
analysis (Figure 1A, B). The negative regulation of Ras 
on galectin-7 expression is probably mediated through the 
consequent activation of the JNK‒c-jun pathway, because 
the inhibition of JNK by SP600125 or dn‒c-jun, but not 
inhibitors of other Ras signaling pathways, reproduced the 
FTS-induced increase in galectin-7 protein seen in ST88-
14 and T265P21 cells (Figure 2A‒C and Supplementary 
Figure 2A). Moreover, FTS treatment itself inhibited c-jun 
phosphorylation (Figure 3A). 
Bioinformatics analysis of galectin-7 upstream 
elements revealed predicted AP-1/c-jun and p53 regulatory 
elements. The role of p53 in galectin-7 induction has been 
well established [24, 26, 30] [31]. In conformity with this, 
the FTS-induced increase in galectin-7 was accompanied 
by an increase in the amounts of p53 protein (Figure 
3B). Because galectin-7 was found to increase after Ras 
inhibition, it is reasonable to suggest that the regulation 
of this increase might be mediated by a c-jun-related 
repressor such as JDP2. This protein binds members 
of the AP-1 family such as c-jun, ATF-3, and ATF-2, 
preventing them from exerting their transcription activity 
[74]. The galectin-7 promoter also contains a potential 
JDP2-binding element. Accordingly, inhibition of JDP 
expression by siRNA transfection resulted in a dramatic 
increase in galectin-7 mRNA after FTS treatment (a 5.2-
fold increase compared to FTS-treated control siRNA-
transfected cells, and an increase of 83-fold compared to 
vehicle-treated control si-RNA transfected cells (Figure 
4C, D). Unexpectedly, we also detected an unexplained 
increase in JDP2 mRNA after inhibition of Ras or JNK 
(Figure 4A, B). 
Galectin-7 expression has been shown to sensitize 
cells to apoptosis and enhance cleavage of caspase-3 [32, 
33]. Importantly, stable expression of galectin-7 in ST88-
14 cells rendered them more sensitive to apoptotic signals 
and induced caspase-3 cleavage under normal growth 
conditions (Figure 5B, C). Interestingly, active Ras in 
ST88-14 cells stably expressing galectin-7 was reduced 
in comparison to that in naȉve or GFP-expressing cells 
(Figure 5A).
Studies have shown that expression of galectin-7 is 
induced as a result of cellular stress such as UV irradiation 
[30, 31] and is mediated by p53 [24, 75]. We report 
here, for the first time, that the expression of galectin-7 
is negatively regulated by Ras-GTP. In the MPNSTs of 
NF1 patients, lack of functional neurofibromin leads 
to chronically active Ras. Inhibition of Ras in MPNST 
cells in the present study led to dramatic expression of 
galectin-7, mediated most probably through the FTS-
induced decrease in p-c-jun levels, since inhibition of JNK 
or c-jun yielded similar induction of galectin-7. Notably, 
in two p53-mutated MPNST cell lines, STS26T and 
90-8 [66], no increase in galectin-7 after Ras inhibition 
was detectable. It thus seems that p53 is a key factor in 
galectin-7 expression. Moreover, FTS-induced inhibition 
of Ras significantly increased p53 expression and the 
consequent reduction of survivin in the wild-type p53 
cell lines. Induction of p53 after Ras inhibition has been 
reported in colon cancer [76] and in pancreatic cancer 
[67] cell lines. Inhibition of c-jun was shown to promote 
apoptosis, arguably through a p53-dependent mechanism, 
and to reduce liver cancer in mice [52]. 
We postulate that in NF1-deficient MPNST cells, 
high Ras activity results in low p53 levels together with 
intense c-jun phosphorylation. P-c-jun then heterodimerize 
with JDP2 to inhibit the galectin-7 promoter. Ras 
inhibition induced by FTS treatment increases p53 
levels, thereby triggering p53-dependent galectin-7 
transcription. The FTS-induced Ras inhibition also 
inhibits c-jun phosphorylation, thus dispersing the c-jun/
JDP2 heterodimer and allowing galectin-7 transcription. 
Indeed, decreasing JDP2 levels using specific siRNA 
might also disperse the dimer thereby freeing the gal7 
promoter and making the cells more sensitive to FTS-
induced galectin-7 accumulation. High galectin-7 levels 
in turn rendered MPNST cells more sensitive to apoptotic 
factors, promoted the apoptosis process and restrained 
Ras activity, thus sensitizing the cells to chemotherapy 
or radiotherapy. In addition, the secreted galectin-7 
might be taken up by neighboring cells and affect their 
Ras signaling, as previously reported for galectin-1 
[77]. Moreover, we were able to demonstrate a possible 
reciprocity in galectin-7/Ras relations, since galectin-7 
itself reduced Ras activity. This is reminiscent of the effect 
of galectin-1 on stabilizing Ras in its GTP-binding state 
[7]. 
Galectin-1 promotes tumor growth [15, 19-21] 
and has been described as a cytokine-like factor that 
participates in the promotion of tumor angiogenesis 
[17]. Moreover, Ras can be dislodged from the plasma 
membrane by inhibition of galectin-1 employing anti-
sense DNA [7], by application of the anti-angiogenic 
peptide anginex [77], or by disruption (via a point 
mutation (11A) [78]) of its ability to bind Ras. This results 
in a decrease in Ras-GTP and inhibition of the Raf-MEK-
ERK cascade [7, 77, 78]. Previously we indeed observed 
that anginex significantly inhibits proliferation of NF1-
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deficient MPNST cells (unpublished data). Thus, Ras-GTP 
might cooperate with galectin-1 to induce tumorigenicity 
in NF1-deficient cells, while “shutting down” galectin-7 
expression. 
Altogether, these results point to a galectin-1/
galectin-7 switch, in which FTS-induced Ras inhibition 
reverses the expression pattern of MPNST galectins, as 
suggested in the model in Figure 6. Galectin-7 reportedly 
has some effects that oppose those of galectin-1: whereas 
galectin-1 promotes tumor growth [15, 19-21] and induces 
resistance to apoptosis, galectin-7 induces apoptosis in 
several types of cancer cells [28, 32]. It is tempting to 
speculate on the presence of a mechanism of inhibitory 
cross-talk in which in several transformed cells, and 
particularly in NF1-deficient MPNSTs, high Ras activity 
stimulates galectin-1 and inhibits galectin-7 expression. 
Inhibition of Ras-GTP by FTS decreases galectin-1 
expression, promoting inhibition of cell transformation 
while increasing galectin-7 expression with resulting 
heightened sensitivity to apoptosis.
MATERIALS AND METHODS
cell culture
The human MPNST cell lines ST88-14, T265P21, 
90-8 (NF1‒/‒) and the STS26T cell line (NF1+/+) were a 
kind gift from Dr. Nancy Ratner (Cincinnati Children’s 
Hospital and Medical Center, University of Cincinnati). 
All cell lines were routinely checked for mycoplasma, 
maintained, and subjected to genetic analysis, as described 
earlier [44]. Cells were plated at 0.75 × 106 cells per 10-cm 
dish or 20 × 104 cells per 6-well plate.
Materials
FTS was a kind gift from Concordia 
Pharmaceuticals. Cycloheximide was from Sigma-Aldrich, 
(St. Louis, MO) and LY294002, U0126, SB203580, and 
SP600125 were from Calbiochem (San Diego, CA). The 
antibodies used were: pERK (Sigma-Aldrich); ERK, 
p-c-jun (Serine 63), c-jun (Santa Cruz Biotechnology, 
Santa Cruz, CA); pAkt, Akt, p-p38 (Thr180/Tyr182), 
p38, survivin, and GAPDH (Cell Signaling Technology, 
Danvers, MA); galectin-1 (PeproTech, Rocky Hill, 
NJ); galectin-7 (Abcam, Cambridge, MA); pan-Ras 
(Calbiochem); green fluorescent protein (GFP); naȉve 
goat IgG, horeseradish peroxidase-conjugated goat anti-
mouse IgG or goat anti-rabbit IgG were from Jackson 
ImmunoResearch Laboratories (West Grove, PA).
The following plasmids were used: PEF1 and 
PEF1-galectin-7 were the kind gift of Fu-Tong Liu [32]. 
pEGP-TAM67 (TAM67) [62] was a kind gift from Prof. 
Lily Vardimon (Department of Biochemistry, Tel Aviv 
University). pBabe-Gal7 was generated by amplifying 
galectin-7 with primers containing the restriction enzymes 
HindIII (forward) and KpnI (reverse), cloned into 
PGEM®-T-Easy (Promega), then digested with BamHI/
SalI and cloned into pBabe-Puro digested with BamHI/
SalI.
Protein bands were quantified by densitometry with 
Image EZQuant-Gel software (EZQuant Ltd., Tel Aviv, 
Israel).
Ras-GTP assays
Lysates containing 0.5 mg protein were used to 
measure Ras-GTP by the glutathione S-transferase fused 
to the Ras-binding domain of Raf (GST-RBD) pull-down 
assay as described [63]. The lysates were then western-
blotted with pan-Ras Ab, as described above.
RT‒PCR analysis
Extracts of total RNA (1 µg) were reverse-
transcribed in a total volume of 20 µl using the Verso™ 
RT–PCR Kit (Thermo Scientific, Rockford IL, USA 
) according to the manufacturer’s instructions. cDNA 
samples (1 µg) were used for RT–PCR (QPCR SYBR® 
Green Mix Plus ROX Vial; ABgene, [Epsom, UK]). 









GUSB was used as a reference gene for 
normalization of relative mRNA expression.
Fluorescence-activated cell sorter analysis
ST88-14 cells seeded in 6-well plates were treated 
as described in figure legends, and were then collected and 
washed with phosphate-buffered saline (PBS). Cells were 
subjected to Annexin-V-PI kit according to manufacturer’s 
instructions (BD biosciences, Franklin Lakes, NJ USA) 
and analyzed by fluorescence-activated cell sorter (FACS; 
FACSCalibur, Becton Dickinson, Los Angeles, CA). Data 
were analyzed by FlowJo data analysis software package 
(TreeStar, Ashland, OR).
transfections
Plasmid transfection: Transfections with GFP-
Ras(17N), pEGP-TAM67 or GFP (106 cells, 2 μg DNA; 
Ingenio Electroporation, Mirus, Madison, WI) were 
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carried out by electroporation using Amaxa® (Lonza, 
Basel, Switzerland).
Small interfering RNA (siRNA) transfection: ST88-
14 cells were plated 24 h prior to transfection (104 cells 
per well in 12-well plates) and transfected with 50 nM 
ON-TARGETplus JDP2 siRNA oligos as well as ON-
TARGETplus siCONTROL nontargeting pool, using 
DharmaFECT 1 Transfection Reagent (Thermo Fisher 
Scientific) according to the manufacturer’s instructions. 
As an indicator of transfected cells, we used the siGLO 
Green transfection indicator (Thermo Scientific), followed 
by treatments as described in the figure legends.  
Infections 
Retroviruses were produced by standard protocols, 
as described [64]. Infected cells were allowed to recover 
and were selected by puromycin (1 μg/ml). Expression 
was validated by western blotting and fluorescence 
microscopy. Cells were maintained in growth medium 
containing 0.5 μg/ml puromycin, and subjected to routine 
analysis.
statistical calculations
Significant differences between the results 
obtained by the experimental and the control groups 
in each experiment were determined by paired or 
unpaired Student’s t test, as appropriate, using Microsoft 
Excel. P-values that were equal to or smaller than 0.05 
were considered significant. Data are presented as 
means  ±  standard error of the mean (SEM). Statistical 
significance at p-values of * ≤ 0.05, ** ≤ 0.01 and *** ≤ 
0.001 are indicated.
Image processing
Adobe Photoshop was employed to adjust for 
brightness/contrast or cropping of images. The promoter 
region of galectin-7 was analyzed using Genomatix 
Genome Analyzer (Genomatix Software GmbH [65]).
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